Becospray

Becospray is a synthetic corticosteroid used by the inhaled and intranasal routes for the long-term maintenance treatment of chronic inflammatory airway and nasal conditions. It is not a rescue medicine for acute symptom relief.

Established / FDA-Approved Uses

• Maintenance treatment of asthma (oral inhalation) — as prophylactic, regular anti-inflammatory therapy in adults and children (age per specific product labeling) with asthma requiring inhaled corticosteroid therapy, including patients previously requiring or currently taking oral corticosteroids.
• Seasonal and perennial allergic rhinitis (intranasal spray) — for relief of nasal symptoms (congestion, sneezing, rhinorrhea, itching) in adults and adolescents/children (per product labeling).
• Prevention of recurrence of nasal polyps after surgical (polypectomy) removal (intranasal, in some formulations).

Important Note

Becospray inhalation is not indicated for the relief of acute bronchospasm or status asthmaticus, where a fast-acting bronchodilator (rescue inhaler) is required instead.

Becospray is available in the following common dosage forms:

• Oral inhalation aerosol / dry powder inhaler: delivering Becospray in metered strengths (commonly 50 mcg, 100 mcg, or 250 mcg per actuation, depending on brand/market).
• Intranasal spray (aqueous suspension): delivering Becospray in metered strengths (commonly 50 mcg per actuation).

Exact strength and available presentations vary by brand; check the product label of the dispensed brand for the precise strength of Becospray it contains.

Becospray is a synthetic, halogenated corticosteroid with potent local (topical) anti-inflammatory activity. When administered by inhalation or as a nasal spray, Becospray acts predominantly at the site of deposition (the airway or nasal mucosa) with comparatively low systemic exposure compared to oral corticosteroids.

After deposition on the respiratory or nasal mucosa, Becospray is hydrolyzed by esterases to its more pharmacologically active metabolite, beclomethasone-17-monopropionate (17-BMP), which is responsible for most of the anti-inflammatory effect.

Mechanism of Action

Becospray diffuses across cell membranes of airway/nasal mucosal cells and binds to cytoplasmic glucocorticoid receptors with high affinity. The activated receptor complex modulates gene transcription, resulting in:

• Inhibition of the synthesis and release of inflammatory mediators (cytokines, prostaglandins, leukotrienes).
• Reduced recruitment and activation of eosinophils, mast cells, and other inflammatory cells in the airway/nasal mucosa.
• Decreased mucosal edema, mucus secretion, and airway/nasal hyperresponsiveness.

Pharmacokinetics

Following inhalation or intranasal administration, a portion of the dose is deposited locally (target site) and a portion is swallowed and absorbed systemically from the gastrointestinal tract, but undergoes extensive first-pass hepatic metabolism, limiting systemic bioavailability. Becospray is hydrolyzed to the active metabolite beclomethasone-17-monopropionate (17-BMP), which is further metabolized and eliminated mainly in feces, with a smaller fraction in urine.

Oral Inhalation (Aerosol Inhaler)

• Shake the inhaler well before use and prime it as directed if used for the first time or after a period of non-use.
• Breathe out fully, place the mouthpiece in the mouth, and inhale slowly and deeply while actuating the device, then hold the breath for about 10 seconds.
• A spacer device may be used, especially in children, to improve lung deposition and reduce oropharyngeal deposition.
• Rinse the mouth with water and spit it out after each inhaled dose to reduce the risk of oral candidiasis (thrush) and hoarseness.

Intranasal Spray

• Prime the spray pump before first use or after prolonged non-use, as directed on the label.
• Blow the nose gently to clear nasal passages before use.
• Tilt the head slightly forward, insert the nozzle into one nostril pointing slightly away from the nasal septum (away from the midline), and spray while gently inhaling; repeat in the other nostril as directed.
• Avoid spraying directly onto the nasal septum to reduce the risk of septal irritation or perforation with long-term use.

Becospray is for inhaled/intranasal use only and must not be swallowed, injected, or used as eye/ear drops unless a specific product is labeled for that route.

Strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, clarithromycin): may increase systemic exposure to Becospray and its active metabolite, raising the risk of systemic corticosteroid effects, including adrenal suppression and Cushingoid features. Concomitant use should generally be avoided; if unavoidable, monitor closely for corticosteroid-related adverse effects.

Other corticosteroids (systemic or other inhaled/nasal/topical products): concurrent use increases the total corticosteroid burden and risk of systemic side effects (HPA-axis suppression); avoid unnecessary concomitant use and inform the physician about all corticosteroid-containing products being used.

Always inform the prescriber of all medicines being taken, including OTC products, before starting Becospray .

Local Effects

• Inhaled route: oral/oropharyngeal candidiasis (thrush), hoarseness, dysphonia, throat irritation, cough — largely reduced by rinsing the mouth after use and using a spacer.
• Intranasal route: nasal irritation, dryness, burning, epistaxis (nosebleeds), and, rarely with prolonged/incorrect use, nasal septal perforation.

Systemic Effects (generally uncommon at recommended doses, more likely with high-dose or prolonged use)

• Hypothalamic-pituitary-adrenal (HPA) axis suppression.
• Reduced growth velocity in children (see Use in Special Populations).
• Increased susceptibility to infections; unmasking of latent infections.
• Increased risk of pneumonia has been reported with inhaled corticosteroids, particularly in patients with COPD.
• Cataracts, glaucoma, and increased intraocular pressure with long-term use.
• Hypersensitivity reactions (rash, urticaria, angioedema, bronchospasm) — uncommon.

Pregnancy: Data on inhaled/intranasal corticosteroids in pregnancy are reassuring for the low systemic doses typically used, but Becospray should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus. Uncontrolled asthma itself poses risks to both mother and fetus, so therapy should not be stopped without medical advice. Infants born to mothers who received substantial corticosteroid doses during pregnancy should be observed for signs of hypoadrenalism.

Lactation: It is not well established whether clinically significant amounts of Becospray are excreted in human breast milk; because systemic absorption from inhaled/intranasal use is low, it is generally considered compatible with breastfeeding when used at recommended doses, but a physician should be consulted before use while breastfeeding.

• Becospray is not a bronchodilator and must not be used for the relief of acute bronchospasm or acute asthma exacerbations; patients should have a separate fast-acting rescue inhaler available.
• Use with caution in patients with active or quiescent tuberculosis or other respiratory fungal, viral, or bacterial infections, due to the local immunosuppressive effect of corticosteroids.
• Prolonged use of high doses may lead to HPA-axis suppression; patients transferring from systemic to inhaled/intranasal corticosteroids require careful monitoring and gradual withdrawal of systemic steroids under medical supervision.
• May cause a reduction in growth velocity in children and adolescents; growth should be monitored regularly during prolonged therapy.
• Inhaled corticosteroids, including Becospray , have been associated with an increased risk of pneumonia in patients with COPD; remain vigilant for signs of pneumonia in this population.
• Regular eye examinations are advisable with long-term use due to potential risk of cataracts and glaucoma.
• Avoid spraying the nasal product directly onto the nasal septum to reduce the risk of septal perforation; discontinue and seek medical advice if signs of nasal septal injury occur.
• Use with caution in patients with hepatic impairment, as metabolism of Becospray may be altered.
• Do not discontinue Becospray abruptly if used regularly for asthma or rhinitis control without consulting a physician.

Acute over-inhalation or accidental ingestion of a single extra dose of Becospray is unlikely to cause significant harm because systemic absorption is low. However, chronic use of doses higher than recommended may result in systemic corticosteroid effects, including suppression of HPA-axis function.

In case of a suspected overdose, or if excessive/prolonged use has occurred, seek immediate medical attention or contact a poison control center. Do not attempt to manage a suspected overdose at home; a physician may need to monitor adrenal function and taper corticosteroid exposure gradually if chronic overuse has occurred.

Store at room temperature (below 30°C), away from light and moisture. Do not puncture, break, or burn the aerosol canister, even when apparently empty, and avoid exposure to extreme heat or direct sunlight. Keep out of reach of children.

Pediatric Use

Becospray may be used in children within the age range specified by the individual product's labeling (commonly from about 5–6 years and above, depending on the formulation and brand); safety and efficacy in younger children have not been established for most formulations. Long-term use may reduce growth velocity; growth should be monitored periodically.

Geriatric Use

No specific dose adjustment is generally required in elderly patients; the lowest effective dose should be used and patients monitored for corticosteroid-related adverse effects, including bone health.

Hepatic Impairment

Use with caution; systemic exposure to Becospray may theoretically be increased due to altered hepatic first-pass metabolism, although clinical data are limited.

Renal Impairment

No specific dose adjustment is established; Becospray has not been extensively studied in renal impairment given its predominantly local action and low systemic exposure.

Becospray is intended for regular, ongoing maintenance use rather than short-term or as-needed treatment. For asthma, therapeutic benefit typically develops over several days to weeks, and treatment is usually continued long-term with periodic reassessment by the physician to find the lowest effective maintaining dose. For seasonal allergic rhinitis, Becospray may be used for the duration of the allergy season, starting before expected exposure where possible; for perennial rhinitis, longer-term regular use may be required. Duration should always be guided by an individual treatment plan set by the prescriber.

Corticosteroids (Glucocorticoids); Inhaled and Intranasal Anti-inflammatory Agents; Anti-asthmatic and Anti-allergic Agents

Becospray exerts potent local anti-inflammatory activity by binding to intracellular glucocorticoid receptors in airway and nasal mucosal cells, modulating gene transcription to reduce the production of inflammatory cytokines, prostaglandins, and leukotrienes, decrease eosinophil and mast cell activity, and reduce mucosal edema and hyperresponsiveness. Becospray is metabolized to its more active metabolite, beclomethasone-17-monopropionate, which is largely responsible for its anti-inflammatory action, while low systemic bioavailability from the inhaled/intranasal route limits systemic corticosteroid exposure at recommended doses.

C

Becospray is approved for use in children within the age range defined by the specific product's labeling — commonly from around 5 years of age for oral inhalation and around 6 years of age for intranasal use, though this varies by brand and formulation. Safety and efficacy have not been established below the labeled minimum age for a given product.

In pediatric patients, Becospray should be used at the lowest effective dose, and growth velocity should be monitored periodically during prolonged treatment, since inhaled/intranasal corticosteroids, including Becospray , may cause a reduction in growth velocity. A pediatrician should weigh the benefits of asthma/rhinitis control against this potential risk for each child.